Crispr
CRISPR - Genetic ImprovementsEDIT and CRSP
CRISPR-Cas9, -Cas11, -Cas12 genetic improvements for bio-pharma partnerships
The next big thing to improving and repairing defects in you RNA
Currently at Fibretracement 0.618 and in spot to move up or down, depending on big money theory...wahahah!
but there's enough small money to pull it down, just saying for disclosure.
Investing In Genomics Anyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment opportunities and ideas all over the world. Start with what you know and what you are involved in, in your day to day life’’. Following this advice, I will share what I think is a potentially fantastic opportunity for readers interested in investing in healthcare. This opportunity lies in CRISPR.
Looking back in recent history, it took over 13 years and an immense amount of computing power to map out the human genome. The process started in 2001 and cost 2.7 billion USD, 12 years later in 2012 CRISPR based genome-editing was birthed. In 2013 the cost to sequence a human genome has dropped from 2.7billion USD to 1000 USD. This deflationary trend is projected to continue into the 2020s and 2030s thus implying human gene sequencing will get cheaper and more affordable over time. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome-editing platform that dares to address the most salient health issues. read more at www.patreon.com
NASDAQ:CRSP
Many Thanks.
R.M.D
CRISPR Stocks I TrackIf you aren't familiar yet with CRISPR technology, check out this Radiolab podcast and then this update.
NTLA - Inverse head & shouldersAn inverse head & shoulders pattern formed in the charts of Intellia, a company developing CRISPR gene-editing therapy. While CRISPR has not been approved to begin human trials in the US, it has already been tested on over 80 patients in China.
Target: $31 (previous closing high), or long term hold
Stop: $18 - $20
Weekly with Median LineUnconventional Median Line on the weekly.
Pattern on watch.
What is CRISPR?
wwwuser.cnb.csic.es
Informational only, not a recommendation to buy or sell any security.
EDIT off the bounce on low volume.Nice support level at $20
Filled Gap up and Gap down.
If decent trading volume, long term investors or proponents to CAS-9 research will buy in at these support levels.
CRISPR got upgraded.
EDITAS holds patents that relate to the use of CRISPR-Cas9 in the cells of humans and other eukaryotes, while the UC Berkeley, Crispr, patents cover use of the gene-editing approach more generally.
Licensing plays from one company to the other. No profit in the near term. Bump in stock off Crispr viral news.
